Direct oral anticoagulants (DOACs), including the factor IIa inhibitor, dabigatran and factor Xa inhibitors, rivaroxaban, apixaban and edoxaban, have been approved for the treatment of thrombosis, the prevention of thromboembolism in orthopedic post-operative patients, and the prevention of thromboembolic strokes in patients with atrial fibrillation (AF); with respect to the latter, DOACs have been demonstrated to be non-inferior to warfarin in clinical effectiveness [1–5]. Here, F10 is linked to atrial fibrillation.